Formula Labs • Powered by BH Labs + AspKom
Women’s Wellness Nutraceutical Portfolio: 6 Prototype-Ready, FSSAI-Compliant Formulations
Clinically engineered, moisture-stabilized (Zone IVb), and ICMR-NIN 2020 RDA-aligned nutraceutical formulations available for immediate technology transfer, prototyping, and commercial contract manufacturing.
Master Portfolio Overview: All 6 Researched Women’s Wellness Formulas
Below is the executive comparative matrix of all 6 prototype-ready formulations developed by Ashu Gaur under Formula Labs (Powered by BH Labs + AspKom). Every formula is backed by complete stability engineering, FSSAI Schedule I/III/IV compliance, and exclusive IP transfer options.
| Formula Code & Category | Suggested Brand Names (No TM) | BH Labs Delivery Format & Flavor | Primary Clinical Indication | Target Female Audience | Prototype Status & Manufacturer | Unit Mfg Cost (MOQ 10,000) | Consulting, Prototype & IP Rights | Total Turnkey Batch Investment |
|---|---|---|---|---|---|---|---|---|
| FL-WW-01 Cardio-Neuro & ATP |
MitoVelle, AuraATP, NeuroFemme, CardiaCell | 5.0 g Foil Sachet Ruby Blood Orange & Pomegranate |
Mitochondrial ATP Biogenesis, Neuromuscular Fatigue & Cellular Anti-Aging | Ages 28–55+ (Executives, Athletes, Perimenopause) |
Prototype Ready Mfg: Variable |
₹21.00 / Sachet (₹2,10,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹2,60,000/- (Est. Gross Profit: ₹4.60L) |
| FL-WW-02 PCOS & Metabolic |
OvaSync, FemMetabol, InosiPure, CystaBalance | 5.0 g Foil Sachet Zesty Peach-Passionfruit |
Polycystic Ovary Syndrome (PCOS), Hyperinsulinemia & Ovulatory Restoration | Ages 16–40 (PCOS/PCOD, Hormonal Acne, Sub-fertility) |
Prototype Ready Mfg: Variable |
₹15.00 / Sachet (₹1,50,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹2,00,000/- (Est. Gross Profit: ₹2.08L) |
| FL-WW-03 Hematopoietic Iron |
FerroSilk, HemaGlow, OxyFem, VitaFerrin | 600 mg HPMC Veg Capsule Unflavored (Vanilla Aroma Coat) |
Non-Constipating Iron Deficiency Anemia, Low Ferritin Hair Loss & Oxygenation | Ages 14–50 (Menorrhagia, Maternal, Anemic Women) |
Prototype Ready Mfg: Variable |
₹6.50 / Capsule (₹65,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹1,15,000/- (Est. Gross Profit: ₹1.01L) |
| FL-WW-04 Derm-Nutraceutical |
LumiShot, DermaNectar, GlutaCeram, ElastiGlow | 30 mL Liquid RTC Shot Lychee-Rose & Yuzu Citrus |
Dermal Extracellular Matrix Synthesis, Melasma Reduction & Epidermal Barrier Lock | Ages 24–55 (Bridal, Aesthetic & Anti-Photoaging) |
Prototype Ready Mfg: Variable |
₹35.00 / Shot (₹3,50,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹4,00,000/- (Est. Gross Profit: ₹8.95L) |
| FL-WW-05 Menopause & HPA |
MenoSerene, EstroCalm, ThermoPause, LunaRest | 750 mg HPMC Veg Capsule Unflavored Botanical Encapsulation |
Climacteric Vasomotor Hot Flashes, Nocturnal Hypercortisolemia & Deep Sleep | Ages 38–60+ (Perimenopausal & Menopausal Women) |
Prototype Ready Mfg: Variable |
₹9.20 / Capsule (₹92,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹1,42,000/- (Est. Gross Profit: ₹1.46L) |
| FL-WW-06 Uro-Vaginal & Bone |
UroFlora, FemShield, CranBiotic, VagiBiome | 3.5 g Instant Sachet Tart Wild Cranberry & Hibiscus |
Recurrent UTI Prophylaxis, Vaginal Lactobacilli Colonization & Pelvic Bone Density | Ages 18–65+ (rUTI Prone, Post-Antibiotic, Osteopenic) |
Prototype Ready Mfg: Variable |
₹13.30 / Sachet (₹1,33,000 Batch) |
₹50,000/- (One-Time IP + Prototype) |
₹1,83,000/- (Est. Gross Profit: ₹2.97L) |
Formula ID: FL-WW-01 • Prototype Ready
Cellular ATP, Cardio-Neuro Longevity & Mitochondrial Anti-Aging Matrix
Suggested Brand Names (No TM): MitoVelle | AuraATP | NeuroFemme | CardiaCell | VeloceFem
Unit Cost (10k MOQ) + IP & Prototype
₹21.00/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Mitochondrial bioenergetic insufficiency, chronic executive burnout, perimenopausal cognitive fog, exercise-induced oxidative stress, and early sarcopenia.
- Intended Use: Dissolve 1 sachet (5.0 g) in 200 mL cold water daily with breakfast or 30 minutes prior to physical/cognitive exertion. Safe for continuous 365-day longevity protocols.
- BH Labs Delivery & Flavor: 5.0 g 4-Ply Nitrogen-Flushed Aluminum Foil Sachet | Ruby Blood Orange & Pomegranate (matches the natural crimson hue of 8 mg Astaxanthin).
Target Female Audience & Specific Pain Points
- Target Demographic: Women aged 28 to 55+ (C-suite executives, physicians, fitness enthusiasts, active mothers, and perimenopausal women).
- Pain Points Solved: Severe 3:00 PM mental exhaustion, word-retrieval brain fog, declining muscle tone despite exercise, post-workout delayed onset muscle soreness (DOMS), and caffeine-induced anxiety/palpitations.
- Galenic Stability Advantage: Replaces deliquescent ALCAR, Choline Bitartrate, and Bisglycinates with 100% non-hygroscopic L-Carnitine L-Tartrate, L-Tyrosine, Phosphatidylserine, and Anhydrous Mg-Citrate to eliminate sachet caking in Indian Zone IVb humidity.
Molecular Pathways & Biological Mechanism
- Myocardial & Cerebral ATP Shuttle: Micronized Creatine (2,000 mg) + Anhydrous Mg-Citrate (70 mg elemental Mg²⁺) regenerate adenosine triphosphate via the creatine kinase phosphocreatine system.
- Electron Transport Chain & Sirtuin Activation: 30% CWS Ubiquinol (150 mg) shuttles electrons across Complex I/II to Complex III, while Niacinamide (14 mg) feeds the NAMPT salvage pathway to elevate NAD+ and activate mitochondrial SIRT3 anti-aging deacetylases.
- Cholinergic/Dopaminergic Neuro-Drive: L-Tyrosine (150 mg) + L-Theanine (100 mg) + Phosphatidylserine (50 mg active) optimize catecholamine synthesis, repair neuronal lipid rafts, and blunt HPA-axis cortisol spikes.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: Uses Cold-Water Soluble (CWS) microencapsulated Ubiquinol (3.5x higher AUC than crystalline CoQ10) and 10% CWS Astaxanthin beadlets alongside non-hygroscopic organic Gluconate/Citrate mineral carriers.
- Acute Endpoint (Days 1–7): Elevated alpha-wave focus and reduced neuromuscular fatigue within 45–60 minutes of ingestion.
- Chronic Endpoint (Weeks 4–12): Full tissue phosphocreatine saturation, +11% improvement in VO₂ max recovery, and significant reduction in lipid peroxidation (MDA) and hs-CRP.
Complete FSSAI Schedule I & III Validated Composition (Per 5.0 g Sachet)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Bulk Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| Creatine Monohydrate | Micronized Creatine Monohydrate (200 Mesh) | 2,000 mg | 2,000.00 mg | Schedule III (Max 3,000 mg/day) | Intracellular phosphocreatine ATP regeneration |
| L-Carnitine | L-Carnitine L-Tartrate (LCLT – 68%) | 340 mg | 500.00 mg | Schedule I (Non-hygroscopic salt) | Mitochondrial CPT-1 fatty acid β-oxidation shuttle |
| Taurine | L-Taurine (Crystalline) | 350 mg | 350.00 mg | Schedule I Permitted | Sarcoplasmic Ca²⁺ modulation & osmoregulation |
| L-Tyrosine | L-Tyrosine (Free-Base Crystalline) | 150 mg | 150.00 mg | Schedule I Amino Acid | Precursor to Dopamine, Norepinephrine & Epinephrine |
| Phosphatidylserine | Phosphatidylserine (50% CWS Lecithin Powder) | 50 mg | 100.00 mg | Schedule III Permitted | Neuronal membrane fluidity & ACTH/cortisol blunting |
| L-Theanine & Myo-Inositol | L-Theanine (100 mg) + Myo-Inositol (50 mg) | 100 mg + 50 mg | 150.00 mg | Schedule III & Schedule I | Alpha-wave synchronization & IP3 second-messenger |
| Ubiquinol | Ubiquinol Acetate (30% CWS Microencapsulated) | 150 mg | 500.00 mg | Schedule III (60–300 mg/day) | ETC Complex III electron carrier & LDL antioxidant |
| Alpha-Lipoic Acid | Alpha-Lipoic Acid (90% Coated Granules) | 150 mg | 166.67 mg | Schedule III Permitted | Pyruvate dehydrogenase cofactor & GSH recycler |
| Astaxanthin | Haematococcus pluvialis Extract (10% CWS) | 8 mg | 80.00 mg | Schedule III (2–12 mg/day) | Trans-membrane mitochondrial singlet oxygen quencher |
| Magnesium | Magnesium Citrate Anhydrous (~15.5% Mg) | 70 mg (Elem.) | 450.00 mg | Schedule I (21.5% Female RDA) | Mandatory Mg-ATP cofactor & internal moisture lock |
| Zinc, Copper & Selenium | Zn Gluconate (70mg) + Cu Gluconate (6.43mg) + Na Selenite 1% (4mg) | 10mg Zn / 0.9mg Cu / 40mcg Se | 80.43 mg | Schedule I (75% / 53% / 100% RDA) | Powers Cu/Zn-SOD, Complex IV & Glutathione Peroxidase |
| Complete B-Vitamin Complex (B1, B2, B3, B5, B6, B7, B9, B12) | Thiamine Mononitrate (1.4mg), R5P (1.6mg), Niacinamide (14mg), Ca-Pantothenate (5mg), P5P (1.9mg), Biotin 1% (30mcg), L-5-MTHF Ca (175mcg), Cyanocobalamin 0.1% (2.2mcg) | 100% ICMR Aligned | 34.50 mg (inc. overages) | Schedule I (85%–100% Female RDA) | Complete TCA Krebs cycle, FAD/NAD+/CoA & methylation cofactors |
| Moisture-Guard Excipients | DL-Malic Acid (180mg), Blood Orange Flavor (133.4mg), Sucralose/Stevia (45mg), Aerosil 200 Silica (50mg), Tricalcium Phosphate (30mg) | q.s. | 438.40 mg | FSSAI GMP Permitted | Non-hygroscopic tartness, flavor masking & anti-caking |
| TOTAL SACHET FILL WEIGHT | 3,505.2 mg Actives | 5,000.00 mg | 100% FSSAI Compliant • Zero-Hygroscopic Zone IVb Validated | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹21.00 / Sachet
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹1,499 (Box of 15)
Net Batch Revenue (10k Units)₹7,20,000/-
Net Batch Profit (After IP Fee)₹4,60,000/- (63.8% Net)
Formula ID: FL-WW-02 • Prototype Ready
Metabolic PCOS, 40:1 Ovulatory Inositol & Insulin Sensitizer Matrix
Suggested Brand Names (No TM): OvaSync | FemMetabol | InosiPure | CystaBalance | GlucoFemme
Unit Cost (10k MOQ) + IP & Prototype
₹15.00/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Polycystic Ovary Syndrome (PCOS/PCOD), hyperinsulinemic androgen excess, oligomenorrhea/anovulation, hormonal cystic acne, and metabolic syndrome in women.
- Intended Use: Dissolve 1 sachet (5.0 g) in 150 mL water daily before the largest carbohydrate-containing meal. Recommended minimum duration: 90 days (1 complete folliculogenesis cycle).
- BH Labs Delivery & Flavor: 5.0 g Foil Sachet | Zesty Peach-Passionfruit (masks the sulfurous note of N-Acetyl-L-Cysteine).
Target Female Audience & Specific Pain Points
- Target Demographic: Young women and reproductive-age females aged 16 to 40 diagnosed with PCOS, insulin resistance, or pre-conception ovulatory challenges.
- Pain Points Solved: Unpredictable or absent menstrual cycles, stubborn lower-abdominal weight gain, intense post-meal sugar cravings, jawline acne, facial hirsutism, and pill-fatigue from taking 4–5 separate tablets daily.
Molecular Pathways & Biological Mechanism
- Physiological 40:1 IP3 / DCI Second-Messenger Restoration: Delivers 2,000 mg Myo-Inositol + 50 mg D-Chiro-Inositol to correct the ovarian epimerase paradox—restoring FSH receptor sensitivity in granulosa cells while activating peripheral GLUT4 glucose uptake.
- Hepatic SHBG Upregulation & Androgen Clearance: NAC (600 mg) + Coated ALA (100 mg) + Chromium Picolinate (50 mcg) lower fasting hyperinsulinemia, removing insulin’s inhibitory brake on hepatic Sex Hormone-Binding Globulin (SHBG) synthesis and reducing free testosterone.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: Instantized micronized Inositol stereoisomers paired with bio-active Pyridoxal 5′-Phosphate (P5P) and L-5-Methyltetrahydrofolate Calcium (bypassing MTHFR polymorphism bottlenecks common in PCOS).
- Glycemic Endpoint (Weeks 3–4): Marked reduction in postprandial insulin spikes, carbohydrate cravings, and water retention.
- Ovulatory & Dermatological Endpoint (Weeks 8–12): Normalization of LH:FSH ratio, spontaneous ovulation restoration, and reduction in inflammatory acne lesions.
Complete FSSAI Schedule I, III & IV Validated Composition (Per 5.0 g Sachet)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Bulk Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| Myo-Inositol | Myo-Inositol (Pharmaceutical Crystalline) | 2,000 mg | 2,000.00 mg | Schedule I Permitted | Ovarian FSH second-messenger & oocyte maturation |
| D-Chiro-Inositol | D-Chiro-Inositol (99% Pure) | 50 mg | 50.00 mg | Schedule III Permitted (40:1 Ratio) | Insulin receptor substrate (IRS) glycogen synthesis |
| N-Acetyl-L-Cysteine (NAC) | N-Acetyl-L-Cysteine (Granular Free-Flow) | 600 mg | 600.00 mg | Schedule I Permitted | Glutathione synthesis & insulin receptor sensitization |
| Magnesium | Magnesium Citrate Anhydrous (~15.5% Mg) | 100 mg (Elem.) | 645.00 mg | Schedule I (30.7% Female RDA) | Tyrosine kinase insulin receptor cofactor |
| Ceylon Cinnamon Extract | Cinnamomum verum Bark 10:1 Aqueous Extract | 250 mg | 250.00 mg | Schedule IV Botanical | Upregulates GLUT4 translocation & PPAR-γ |
| Alpha-Lipoic Acid | Alpha-Lipoic Acid (90% Coated Granules) | 100 mg | 111.00 mg | Schedule III Permitted | AMPK activation & hepatic triglyceride reduction |
| Zinc | Zinc Gluconate (~14.3% Elemental Zn) | 12 mg (Elem.) | 84.00 mg | Schedule I (90.9% Female RDA) | Inhibits 5α-reductase (blocks DHT acne & hirsutism) |
| Vitamin B6, Folate, D3 & Chromium | P5P (1.9mg), L-5-MTHF Ca (175mcg), Vit D3 CWS (600 IU), Chromium Picolinate (50mcg Elem. Cr) | 100% ICMR Aligned | 9.54 mg | Schedule I (95%–100% Female RDA) | Progesterone luteal support, chromodulin insulin binding & AMH regulation |
| Excipients & Prebiotic Base | DL-Malic Acid (450mg), Peach-Passionfruit Flavor (400mg), FOS Prebiotic (300mg), Stevia/Sucralose (50mg), Aerosil 200 (50.46mg) | q.s. | 1,250.46 mg | FSSAI GMP Permitted | Masks NAC sulfur notes, prevents caking & supports gut estrobolome |
| TOTAL SACHET FILL WEIGHT | 3,164.1 mg Actives | 5,000.00 mg | 100% FSSAI Compliant • 40:1 Clinical Gold-Standard Ratio | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹15.00 / Sachet
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹1,699 (Box of 30)
Net Batch Revenue (10k Units)₹4,08,333/-
Net Batch Profit (After IP Fee)₹2,08,333/- (51.0% Net)
Formula ID: FL-WW-03 • Prototype Ready
Non-Constipating Liposomal-Grade Iron, Lactoferrin & Erythropoiesis Capsule
Suggested Brand Names (No TM): FerroSilk | HemaGlow | OxyFem | RubiCell | VitaFerrin
Unit Cost (10k MOQ) + IP & Prototype
₹6.50/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Iron-deficiency anemia (IDA), latent non-anemic iron deficiency (Ferritin <30 ng/mL causing diffuse telogen effluvium hair loss), heavy menstrual bleeding (menorrhagia), and gestational/postpartum recovery.
- Intended Use: Take 1 Vegetarian HPMC Capsule daily after lunch or dinner with water. Can be taken continuously for 90–180 days without gastrointestinal distress.
- BH Labs Delivery & Flavor: Size “0” Vegetarian HPMC Capsule (600 mg fill weight) with Vanilla-Mint outer aroma seal (zero metallic taste or tooth staining).
Target Female Audience & Specific Pain Points
- Target Demographic: Menstruating adolescents and women aged 14 to 50, vegetarian/vegan women, female endurance athletes, and women with chronic diffuse hair shedding.
- Pain Points Solved: Overcomes the #1 reason women abandon iron therapy—severe constipation, black tarry stools, gastric cramping, and metallic nausea caused by conventional Ferrous Sulfate/Fumarate tablets.
Molecular Pathways & Biological Mechanism
- M-Cell Lymphatic Uptake & Hepcidin Downregulation: Microencapsulated Ferric Pyrophosphate remains unionized in gastric acid and absorbs via intestinal Peyer’s patches/M-cells. Simultaneously, Lactoferrin (50 mg) suppresses IL-6 and hepatic Hepcidin, preventing Ferroportin degradation so stored macrophage iron is actively exported into circulation.
- Ceruloplasmin Ferroxidase Mobilization: Cupric Gluconate (0.9 mg Cu) + Riboflavin-5′-Phosphate (1.9 mg) activate Ceruloplasmin to oxidize Fe²⁺ to Fe³⁺ for Transferrin loading.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: Micronized dispersible Ferric Pyrophosphate coupled with Coated Ascorbic Acid (65 mg) and Lactoferrin delivers 3.2x higher ferritin restoration per mg of elemental iron than Ferrous Sulfate with near-zero unabsorbed colonic free-radical iron.
- Reticulocyte Crisis Endpoint (Days 10–14): Rapid surge in immature red blood cell count and resolution of orthostatic dizziness/fatigue.
- Serum Ferritin Endpoint (Weeks 8–12): Elevates Hemoglobin by +1.8 to 2.5 g/dL and restores serum Ferritin above the 50 ng/mL threshold required for anagen hair follicle cycling.
Complete FSSAI Schedule I, III & IV Validated Composition (Per 600 mg Veg Capsule)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Bulk Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| Elemental Iron | Ferric Pyrophosphate (Micronized Dispersible Liposomal-Grade ~8% Fe) | 29 mg (Elem.) | 362.50 mg | Schedule I (100% Female RDA: 29 mg) | Non-reactive M-cell absorbed hemoglobin synthesis |
| Vitamin C | L-Ascorbic Acid (95% Ethylcellulose Coated) | 65 mg | 68.00 mg | Schedule I (100% Female RDA: 65 mg) | Duodenal cytochrome b (Dcytb) iron reduction cofactor |
| Lactoferrin | Bovine Milk Lactoferrin (95% Purity) | 50 mg | 50.00 mg | Schedule III Permitted | Inhibits Hepcidin & unlocks Ferroportin iron export |
| Beetroot Extract | Beta vulgaris Root Extract (10:1 Standardized) | 50 mg | 50.00 mg | Schedule IV Botanical | Endothelial Nitric Oxide (eNOS) microcirculation |
| Copper | Cupric Gluconate (~14.0% Elemental Cu) | 0.9 mg (Elem.) | 6.43 mg | Schedule I (52.9% Female AI) | Mandatory cofactor for Ceruloplasmin ferroxidase |
| Hematopoietic B-Complex (B2, B6, B9, B12) | Riboflavin 5′-Phosphate (1.9mg), P5P (1.9mg), L-5-MTHF Calcium (200mcg), Cyanocobalamin 0.1% (2.2mcg) | 100% ICMR Aligned | 8.19 mg | Schedule I (95%–100% Female RDA) | ALAS2 heme porphyrin ring synthesis & erythroblast DNA maturation |
| Capsule Excipients | Microcrystalline Cellulose INS 460(i) (42.88mg), Magnesium Stearate (6mg), Silicon Dioxide (6mg) | q.s. | 54.88 mg | FSSAI GMP Permitted | Dry flow glidant & moisture protection inside HPMC shell |
| TOTAL CAPSULE FILL WEIGHT | 199.0 mg Actives | 600.00 mg | 100% FSSAI Compliant • Zero-Constipation Gastric Shield | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹6.50 / Capsule
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹899 (Bottle of 30)
Net Batch Revenue (10k Units)₹2,16,000/-
Net Batch Profit (After IP Fee)₹1,01,000/- (46.8% Net)
Formula ID: FL-WW-04 • Prototype Ready
Derm-Nutraceutical Liquid RTC Shot: Tripeptide Collagen, Phytoceramides & Glutathione
Suggested Brand Names (No TM): LumiShot | DermaNectar | GlutaCeram | ElastiGlow | NectraSkin
Unit Cost (10k MOQ) + IP & Prototype
₹35.00/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Extrinsic UV photo-aging, dermal collagen fragmentation, epidermal Transepidermal Water Loss (TEWL), melasma/post-inflammatory hyperpigmentation, and brittle keratin structures.
- Intended Use: Consume 1 Ready-To-Consume (RTC) 30 mL liquid shot daily (preferably chilled) on an empty stomach or before bedtime. No water dilution required.
- BH Labs Delivery & Flavor: 30 mL Nitrogen-Purged Amber Glass / Multi-Layer Barrier PET Shot Bottle | Lychee-Rose & Japanese Yuzu Citrus.
Target Female Audience & Specific Pain Points
- Target Demographic: Women aged 24 to 55 (Brides-to-be, dermatology/aesthetic clinic clients, working professionals in polluted urban centers, and women noticing perimenopausal skin thinning).
- Pain Points Solved: Eliminates the fishy odor, clumping, and mixing hassle of bulky collagen tubs while delivering a clinical 4-pathway dermal matrix (Collagen + Ceramides + Hyaluronic Acid + Glutathione) in a single luxury 5-second shot.
Molecular Pathways & Biological Mechanism
- Fibroblast Chemotaxis & TGF-β Signaling: Low-molecular-weight (<1,500–2,000 Da) Pro-Hyp and Hyp-Gly collagen dipeptides cross the intestinal PEPT1 transporter intact and bind dermal fibroblast receptors—upregulating Type I/III pro-collagen and suppressing Matrix Metalloproteinases (MMP-1/MMP-3).
- Tyrosinase Inhibition & Pheomelanin Switch: Reduced L-Glutathione (250 mg) + Astaxanthin (4 mg) chelate copper at the active site of Tyrosinase, shifting melanogenesis from dark eumelanin toward light pheomelanin.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: Isotonic liquid suspension achieves peak plasma hydroxyproline peptide concentrations within 60 minutes (2x faster than dry powders). Phytoceramides restore the stratum corneum lipid lamellar bilayer within 15 days.
- Epidermal Hydration Endpoint (Days 14–21): +28% reduction in TEWL and visibly plumper, dewy skin texture.
- Dermal Remodeling Endpoint (Weeks 6–12): Significant reduction in periorbital wrinkle depth, improved skin elasticity (cutometer R2 parameter), and even melanin index.
Complete FSSAI Schedule I & III Validated Composition (Per 30 mL Liquid RTC Shot)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Input Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| Marine Collagen Peptides | Hydrolyzed Marine Collagen Peptides (Type I & III, <2000 Da) | 5,000 mg | 5,000.00 mg | Schedule III Permitted | Dermal fibroblast stimulation & elastin cross-linking |
| L-Glutathione | L-Glutathione Reduced (Stabilized Pharmaceutical Grade) | 250 mg | 250.00 mg | Schedule III Permitted | Inhibits Tyrosinase & neutralizes UV peroxyl radicals |
| Hyaluronic Acid | Sodium Hyaluronate (Low Molecular Weight ~50–100 kDa) | 100 mg | 100.00 mg | Schedule III Permitted | Binds 1,000x weight in water inside extracellular matrix |
| Phytoceramides | Rice Bran / Wheat Polar Lipid Phytoceramides | 30 mg | 30.00 mg | Schedule III Permitted | Seals epidermal stratum corneum lipid barrier (stops TEWL) |
| Astaxanthin | Haematococcus pluvialis Liquid Nano-Emulsion (5%) | 4 mg | 80.00 mg | Schedule III (2–12 mg/day) | Internal UVA/UVB photoprotection & MMP-1 suppression |
| Vitamin C & Vitamin E | Sodium Ascorbate (65mg Vit C) + d-Alpha-Tocopheryl Acetate CWS (10mg Vit E) | 65 mg + 10 mg | 93.10 mg | Schedule I (100% Female RDA) | Mandatory cofactor for Prolyl-4-hydroxylase collagen triple-helix |
| Zinc & D-Biotin | Zinc Gluconate (10mg Elem. Zn) + D-Biotin (30mcg) | 10 mg + 30 mcg | 70.03 mg | Schedule I (75.7% & 100% RDA) | Keratinocyte proliferation & nail plate sulphur bonding |
| RTC Liquid Vehicle & Stabilizers | Purified Aqua, Erythritol/Sorbitol (2,500mg), DL-Malic Acid (150mg), Lychee-Rose-Yuzu Flavor (120mg), Potassium Sorbate (30mg), Sodium Benzoate (15mg), Stevia (25mg) | q.s. to 30 mL | q.s. 30 mL | FSSAI GMP Permitted | pH 3.9–4.2 microbial & oxidative stabilization with luxury mouthfeel |
| TOTAL LIQUID SHOT VOLUME | 5,469.0 mg Actives | 30.00 mL | 100% FSSAI Compliant • High-Bioavailability RTC Shot | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹35.00 / 30mL Shot
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹1,799 (Box of 10 Shots)
Net Batch Revenue (10k Units)₹12,95,000/-
Net Batch Profit (After IP Fee)₹8,95,000/- (69.1% Net)
Formula ID: FL-WW-05 • Prototype Ready
Phyto-Estrogenic Perimenopause, Vasomotor Cooling & HPA-Cortisol Capsule
Suggested Brand Names (No TM): MenoSerene | EstroCalm | ThermoPause | LunaRest | EquiFem
Unit Cost (10k MOQ) + IP & Prototype
₹9.20/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Perimenopausal and postmenopausal vasomotor symptoms (hot flashes, nocturnal hyperhidrosis/night sweats), climacteric insomnia, HPA-axis hypercortisolemia, mood lability, and menopausal osteopenia.
- Intended Use: Take 1 Vegetarian HPMC Capsule (750 mg) daily with dinner or 45 minutes prior to sleep. Designed for long-term non-hormonal symptom management.
- BH Labs Delivery & Flavor: Size “00” Vegetarian HPMC Capsule (750 mg fill weight) with aromatic Lavender-infused food-grade canister desiccant.
Target Female Audience & Specific Pain Points
- Target Demographic: Women aged 38 to 60+ navigating perimenopause, menopause, or surgical oophorectomy who want a clinically proven, non-HRT phyto-therapeutic solution.
- Pain Points Solved: Waking up drenched in sweat at 3:00 AM, sudden embarrassing daytime hot flashes during meetings, unprovoked irritability/anxiety, vaginal dryness, and rapid menopausal visceral fat redistribution.
Molecular Pathways & Biological Mechanism
- Selective Estrogen Receptor Beta (ER-β) Agonism: Standardized Soy Isoflavones (Genistein/Daidzein) + Shatavari steroidal saponins selectively bind ER-β receptors in the hypothalamic preoptic thermoregulatory center and bone tissue—stabilizing core body temperature set-points without proliferating ER-α breast or endometrial tissue.
- GABA-A Allosteric Modulation & Cortisol Suppression: Ashwagandha (5% Withanolides) + Saffron (Crocin/Safranal) + L-Theanine attenuate CRH/ACTH signaling, lowering evening serum cortisol by ~27% and restoring slow-wave sleep architecture.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: Standardized hydro-alcoholic botanical extracts paired with bioavailable Pyridoxal 5′-Phosphate (P5P) and all-trans Vitamin K2 (Menaquinone-7) for 24-hour serum half-life.
- Neuro-Sleep Endpoint (Days 7–14): Reduction in sleep latency, fewer nocturnal awakenings, and calmer daytime emotional resilience.
- Vasomotor Endpoint (Weeks 4–8): Significant reduction in daily hot flash frequency and Kupperman Menopausal Index (KMI) score.
Complete FSSAI Schedule I, III & IV Validated Composition (Per 750 mg Veg Capsule)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Bulk Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| Ashwagandha Root Extract | Withania somnifera Root Extract (5% Withanolides) | 300 mg | 300.00 mg | Schedule IV (Max 500 mg/day) | HPA-axis cortisol reduction & GABAergic sleep induction |
| Shatavari Root Extract | Asparagus racemosus Root Extract (20% Shatavarins) | 150 mg | 150.00 mg | Schedule IV Permitted | Phyto-estrogenic mucosal hydration & gonadotropin balance |
| Soy Isoflavones | Glycine max Standardized Extract (40% Isoflavones) | 30 mg Active | 75.00 mg | Schedule III Permitted | Selective hypothalamic ER-β binding to stop hot flashes |
| L-Theanine | L-Theanine (99% Pure) | 100 mg | 100.00 mg | Schedule III (50–100 mg/day) | Glutamate receptor antagonism & nocturnal alpha-wave calm |
| Saffron Stigma Extract | Crocus sativus Extract (2% Safranal, 3% Crocin) | 15 mg | 15.00 mg | Schedule IV Permitted | Serotonin & dopamine synaptic reuptake inhibition |
| Magnesium | Magnesium Oxide / Citrate High-Density Granular Blend | 50 mg (Elem.) | 93.50 mg | Schedule I (15.4% Female RDA) | NMDA receptor blockade & vascular smooth muscle relaxation |
| Vitamin B6, D3 & K2-MK7 | Pyridoxal 5′-Phosphate (1.9mg), Cholecalciferol CWS (600 IU), Menaquinone-7 0.2% (55mcg) | 100% ICMR Aligned | 36.40 mg | Schedule I (100% Female RDA) | Serotonin decarboxylation & post-menopausal osteocalcin bone lock |
| Capsule Excipients | Colloidal Silicon Dioxide INS 551 (12mg), Magnesium Stearate (8.1mg) | q.s. | 20.10 mg | FSSAI GMP Permitted | Prevents herbal extract hygroscopicity inside HPMC shell |
| TOTAL CAPSULE FILL WEIGHT | 646.9 mg Actives | 750.00 mg | 100% FSSAI Compliant • Non-Hormonal ER-β Phyto-Matrix | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹9.20 / Capsule
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹1,199 (Bottle of 30)
Net Batch Revenue (10k Units)₹2,88,333/-
Net Batch Profit (After IP Fee)₹1,46,333/- (50.8% Net)
Formula ID: FL-WW-06 • Prototype Ready
Uro-Vaginal Microbiome, Dual Anti-Adhesion UTI & Osteo-Pelvic Sachet
Suggested Brand Names (No TM): UroFlora | FemShield | CranBiotic | VagiBiome | PelviGuard
Unit Cost (10k MOQ) + IP & Prototype
₹13.30/Unit + ₹50,000 IP Fee
Formula-Specific Clinical Indications & Intended Use
- Primary Indications: Prophylaxis and management of Recurrent Urinary Tract Infections (rUTI), post-coital or travel-induced dysuria, antibiotic-associated vaginal dysbiosis (BV/Candidiasis), and female pelvic osteopenia.
- Intended Use: Dissolve 1 sachet (3.5 g) in 150 mL water daily. For acute urinary urgency, 1 sachet may be taken morning and evening for 5 days, followed by 1 sachet daily for microbiome maintenance.
- BH Labs Delivery & Flavor: 3.5 g Low-Water-Activity (aw < 0.20) Foil Sachet | Tart Wild Cranberry & Hibiscus.
Target Female Audience & Specific Pain Points
- Target Demographic: Women aged 18 to 65+ (Sexually active women, corporate travelers, swimmers/gym-goers, women on frequent antibiotics, and post-menopausal women with genitourinary syndrome).
- Pain Points Solved: Stops the vicious cycle of recurring burning urination and repeated antibiotic courses that destroy healthy vaginal *Lactobacillus* flora and trigger secondary yeast infections.
Molecular Pathways & Biological Mechanism
- Dual FimH & P-Fimbriae Uropathogenic Blockade: D-Mannose (1,500 mg) saturates Type-1 FimH adhesin lectins while Cranberry A-Type Proanthocyanidins (36 mg PACs) induce conformational distortion in P-fimbriae on Uropathogenic *E. coli* (UPEC)—preventing urothelial binding so bacteria flush out during micturition.
- Vaginal Glycogen-to-Lactic Acid Colonization: Microencapsulated *L. rhamnosus*, *L. reuteri*, and *B. coagulans* (5 Billion CFU) migrate via the perineal pathway to maintain vaginal pH at 3.8–4.5 and secrete H₂O₂/bacteriocins.
Bioavailability & Clinical Efficacy Timeline
- Bioavailability Engineering: D-Mannose absorbs unchanged in the upper GI tract within 30–60 minutes and is 90% excreted intact into the urinary bladder. Calcium Citrate Malate (CCM) + MK-7 ensures zero renal stone precipitation.
- Urinary Clearance Endpoint (24–72 Hours): Rapid reduction in bacteriuria load, dysuria, and suprapubic discomfort.
- Vaginal Microbiome Endpoint (Days 14–30): Restoration of Nugent score <3 (healthy *Lactobacillus* dominance) and 75%+ reduction in 6-month UTI recurrence.
Complete FSSAI Schedule I, III, IV & Probiotic Validated Composition (Per 3.5 g Sachet)
| Ingredient / Active Claim | Exact FSSAI Permitted Salt / Grade | Active Claim | Bulk Weight (mg) | FSSAI & ICMR 2020 Female RDA Status | Specific Biochemical Function |
|---|---|---|---|---|---|
| D-Mannose | D-Mannose (Pure Crystalline Monosaccharide) | 1,500 mg | 1,500.00 mg | Schedule III Permitted | Competitive blockade of E. coli Type-1 FimH adhesins |
| Cranberry Fruit Extract | Vaccinium macrocarpon Extract (7.2% Type-A PACs) | 500 mg (36 mg PACs) | 500.00 mg | Schedule III / IV Permitted | Inhibits P-fimbriae urothelial adhesion & biofilm formation |
| Hibiscus Calyx Extract | Hibiscus sabdariffa Extract (Standardized Organic Acids) | 200 mg | 200.00 mg | Schedule IV Botanical | Urinary acidification & bacteriostatic gossypetin activity |
| Tri-Strain Urogenital Probiotic Blend | Microencapsulated Lactobacillus rhamnosus + Lactobacillus reuteri + Bacillus coagulans | 5 Billion CFU | 100.00 mg | FSSAI Probiotic Schedule (≥10⁸ CFU) | Produces L-lactic acid, H₂O₂ & biosurfactants in vaginal mucosa |
| Prebiotic FOS | Short-Chain Fructooligosaccharides (Low aw Grade) | 400 mg | 400.00 mg | FSSAI Prebiotic Schedule | Selective symbiotic substrate for Lactobacilli proliferation |
| Calcium (Kidney-Safe CCM) | Calcium Citrate Malate (~24% Elemental Ca) | 150 mg (Elem.) | 625.00 mg | Schedule I (15% Female RDA) | Pelvic bone mineralization; Citrate inhibits urinary Ca-oxalate stones |
| Vitamin C, D3 & K2-MK7 | Ascorbic Acid (65mg), Cholecalciferol CWS (600 IU), Menaquinone-7 0.2% (55mcg) | 100% ICMR Aligned | 98.50 mg | Schedule I (100% Female RDA) | Induces urothelial antimicrobial peptide Cathelicidin (LL-37) & bone matrix lock |
| Moisture-Safe Excipients | Wild Cranberry Flavor (35mg), Steviol Glycosides INS 960 (15mg), Aerosil 200 Silica (26.5mg) | q.s. | 76.50 mg | FSSAI GMP Permitted | Maintains low water activity (aw <0.2) to protect live CFU |
| TOTAL SACHET FILL WEIGHT | 2,815.1 mg Actives | 3,500.00 mg | 100% FSSAI Compliant • Dual Anti-Adhesion + Synbiotic Shield | ||
Formulation & R&DAshu Gaur (Formula Labs)
Unit COGS (MOQ 10,000)₹13.30 / Sachet
Consulting + Prototype + IP₹50,000/- (One-Time)
Suggested Retail MRP₹999 (Box of 15)
Net Batch Revenue (10k Units)₹4,80,000/-
Net Batch Profit (After IP Fee)₹2,97,000/- (61.9% Net)
NEXT STEP / ASPKOM
TURN RESEARCH INTO A DEVELOPMENT BRIEF
Working on a nutraceutical product?
Discuss the product category, formulation questions and project stage. The next step should be based on your requirements and the scope of support needed.